Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance

  Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive
  Director of Regulatory Affairs and Quality Assurance

Business Wire

NORCROSS, Ga. -- January 15, 2013

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of
therapeutics that target galectin proteins to treat fibrosis and cancer, today
announced the appointment of Rex Horton as Executive Director of Regulatory
Affairs and Quality Assurance. Mr. Horton is an experienced industry
professional with 20 years of management and leadership experience in global
regulatory affairs matters including drugs, biologics and vaccines.

“Rex Horton has broad range of regulatory affairs and quality leadership
experience that is directly relevant to Galectin Therapeutics development
programs, with expertise spanning preclinical development through new drug
approvals in diverse therapeutic areas, including gastroenterology,” said
Peter G. Traber, MD, President, Chief Executive Officer and Chief Medical
Officer of Galectin. “Rex joins us at an auspicious time in the Company’s
history as we are poised to submit an IND for GR-MD-02 for treatment of
non-alcoholic steatohepatitis (NASH) with fibrosis and expect to initiate a
Phase 1 clinical trial early this year. I am therefore glad to welcome Rex to
our team and expect that he will make significant contributions to Galectin
Therapeutics as we continue to develop a treatment with the promise to
effectively treat these common and deadly disorders.”

“I am extremely pleased to be joining Galectin Therapeutics at a pivotal stage
in the development of its novel carbohydrate compounds for the treatment of
fibrotic disease and cancer,” added Mr. Horton. “The Company has extensive
scientific and development expertise within its organization, and I am
impressed by the balanced strategic vision of the leadership team, which has a
clear long-term focus on developing galectin inhibitors for these serious and
life-threatening indications where significant unmet medical needs still

Mr. Horton most recently was Director of Regulatory Affairs at Chelsea
Therapeutics, where he successfully led the organization through its first NDA
filing and favorable FDA Advisory Committee Meeting. In past leadership roles
at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for
key products including Androgel® Stickpack, Creon® Capsules and Luvox® CR
Capsules. He has also provided chemistry, manufacturing and controls (CMC)
regulatory leadership and support of INDs and NDAs, including Estrogel® and
Androgel® Pump. Mr. Horton was a member of the executive leadership team that
successfully implemented solutions to significant regulatory issues
encountered by Solvay in its interactions with the FDA.

Mr. Horton earned his Bachelor’s degree in industrial/manufacturing & systems
engineering from The Georgia Institute of Technology. He is a member of the
Regulatory Affairs Professional Society (RAPS), Drug Information Association
(DIA) and American Association of Pharmaceutical Scientists (AAPS).

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at

AndroGel® and Creon® are registered trademarks of Abbott Laboratories
(formerly Solvay Pharmaceuticals). Luvox® CR is a registered trademark of
Abbot Products, Inc. EstroGel® is a registered trademark of Merck Canada Inc.

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.


Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
Press spacebar to pause and continue. Press esc to stop.